Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris is well positioned because deucrictibant has shown best-in-class oral HAE potential, delivering an 83% overall monthly attack-rate reduction in CHAPTER-3 and 87% in Type 1/2 patients, with rapid onset, 46% of patients attack free, and a clean safety profile with no treatment-related serious adverse events. The commercial case is strengthened by the drug’s once-daily oral convenience versus injectable peers, physician survey data implying meaningful switching interest, and a large market opportunity supported by management/analyst commentary that U.S. peak sales could reach about $1.2B and global peak sales roughly €720M. Financially, the company ended 2Q26 with $363M in cash, providing runway into 2028 and reducing near-term dilution risk while it advances pivotal treatment and prevention programs with key catalysts in 2027.

Pharvaris is viewed skeptically because its value is concentrated almost entirely in deucrictibant and a single mechanism for hereditary angioedema, leaving the company exposed to pipeline concentration and limited therapeutic diversification. Although the mechanism has precedent for acute HAE attacks, prophylaxis remains unproven, chronic safety is still uncertain, and the oral format may be less effective than injectable therapy in a crowded market with generic and other established options. Financially, Pharvaris is expected to continue net losses until commercialization and likely through the early launch phase, while ongoing development and commercialization efforts may require additional capital with potentially dilutive effects on shareholders.